Bufexamac is an NSAID used to treat skin conditions like atopic eczema and inflammatory dermatoses. Bufexamac is a non-steroidal anti-inflammatory drug (NSAID) under the market name Droxaryl, Malipuran, Paraderm and Parfenac.
- Mechanism
- Curator reviewed · 2 references
The full mechanism of action is unclear. It is proposed that bufexamac acts similarly to other non-steroidal anti-inflammatory drugs to inhibit prostaglandin biosynthesis in vitro, via inhibiting cyclo-oxygenase (COX) enzymes. Systematically administered bufexamac may accumulate preferentially in the adrenal cortex of rats and may play a role in adrenal stimulation; however its topical anti-inflammatory action is likely to be independent of this effect.
- Primary indication
- Indicated for the treatment of various skin conditions, such as atopic eczema and other inflammatory dermatoses.Curator reviewed · 3 structured indications
- Formula / weight
- C12H17NO3 · 223.272 g/mol (avg)
- First approval
- Canada, 1995
- Also known as
- Bufexamic acid · p-Butoxyphenylacetohydroxamic acid
- Code names
- CP-1044-J3
Resolves to
MXJWRABVEGLYDG-UHFFFAOYSA-NSMILESCCCCOC1=CC=C(CC(=O)NO)C=C1What you can answer from here — as of January 17, 2025
Which drugs share a target with Bufexamac, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account